India-first daily coverage of GLP-1 therapy — DCGI approvals, Indian generic launches (Sundae, Noveltreat, Obeda, Semabest…), price cuts, Mounjaro / tirzepatide updates, and trial readouts (STEP, SUSTAIN, SURMOUNT, SELECT).
Govt moves to stop pharmacy ads for Mounjaro, Ozempic and other prescription drugs India Today
India’s food regulator acts against GLP-1 supplement for misleading claims CNBC TV18
FSSAI flags GLP-1 food claims, cracks down on rotten food, pesticide-tainted raisins The Times of India
India’s Food Regulator Acts Against GLP-1 Supplement for Misleading Claims Bloomberg.com
weight loss drug news today semaglutide tirzepatide december 2025 BusinessWorld Online
glp-1 weight loss drugs news may 2026 BusinessWorld Online
The one question doctors say most patients forget to ask before they stop taking Ozempic or Wegovy Yahoo Creators
Tirzepatide Outperforms Semaglutide on Weight and Metabolic Health in New Comparison Bioengineer.org
fda recent review glp-1 weight loss drugs prescribing patterns 2026 BusinessWorld Online
fda concerns unapproved glp-1 drugs used for weight loss 2025 www2.polskieradio.pl
fda approves oral glp-1 weight loss drug july 2025 polskieradio.pl
fda concerns unapproved glp 1 drugs used for weight loss polskieradio.pl
Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data? Yahoo Finance
Novo Nordisk's Liver-Fat Win Meets a Street Waiting for November Proof AD HOC NEWS
Novo goes on deal spree amid semaglutide patent expiries Chemistry World
Semaglutide Normalized Liver Fat in Most Adults With Obesity Pharmacy Times
News articles are aggregated from third-party RSS feeds. GLP-1 Check does not endorse or verify individual articles. Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
